Recent Updates
Recently added Catalysts

Diclofenac 1%

Phase 1

Dysmenorrhea Primary | Small molecule | Other |Dare Bioscience, Inc.|Last Updated: Sep 4, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment42

FDA Designations

No designations recorded

Clinical trial landscape

Diclofenac 1% · 1 trial · 1 indication

Phase 1 1
NCT05752526A Study of Diclofenac Gel in Women With Primary DysmenorrheaDysmenorrhea Primary
COMPLETED42 Analytics
PHASE1COMPLETED
A Study of Diclofenac Gel in Women With Primary Dysmenorrhea
Dysmenorrhea PrimaryUnlock trial analytics

Study Endpoints

Primary Endpoints

Measure the systemic Level of Diclofenac after a single dose of DARE-PDM1
7 days

Evaluate the plasma pharmacokinetics of diclofenac after a single dose of DARE-PDM1

Measure the systemic Level of Diclofenac after three doses of DARE-PDM1
3 days

Evaluate the plasma pharmacokinetics of diclofenac after three doses of DARE-PDM1

Measure the Vaginal Fluid levels of diclofenac after three doses of DARE-PDM1
3 days

Evaluate the vaginal fluid pharmacokinetics of diclofenac after three doses of DARE-PDM1

Measure the Vaginal Fluid levels of diclofenac after a single dose DARE-PDM1
7 days

Evaluate the vaginal fluid pharmacokinetics of diclofenac after a single dose of DARE-PDM1

Number of participants with abnormal vaginal exam findings.
60 days

Compare genital safety of DARE-PDM1 versus placebo through vaginal exams

Number of participants with abnormal laboratory test results.
60 days

Evaluate systemic safety of DARE-PDM1 versus placebo through safety laboratory assessments

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
DARE-PDM1 1% Diclofenac Vaginal GelEXPERIMENTAL1% Diclofenac in 2.5 mL Hydrogel
DARE-PDM1 3% Diclofenac Vaginal GelEXPERIMENTAL3% Diclofenac in 2.5 mL Hydrogel
PlaceboPLACEBO_COMPARATOR2.5 mL Hydrogel

Interventions

NameTypeDescription
Diclofenac 1%DRUGvaginal hydrogel containing 1% Diclofenac
Diclofenac 3%DRUGvaginal hydrogel containing 3% Diclofenac
PlaceboDRUGvaginal hydrogel, no active ingredient
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Females ages 18- 50 years old (inclusive) * Self-assessment of historic dysmenorrhea associated pain level of ≥ 5 on a scale of 0 - 10 in at least one of the following anatomic sites: pelvic/vaginal pain, low back pain, while not using NSAIDs or hormonal contraception. * Non-p...

Countries:Australia
Unlock Eligibility Criteria